Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acthar Gel for Intractable Chronic Migraine
NCT01813591Phase 2Completed
- Sponsor
- Dent Neurosciences Research Center, Inc.
- Start
- Apr 2013
- Primary completion
- Dec 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of repository corticotropin injection in chronic migraine (2 arms), sponsored by Dent Neurosciences Research Center, Inc. Primary endpoint: Average total number of headache days at 30 days. Started Apr 2013; status: completed.
02
Drugs
repository corticotropin injection
03
Conditions
chronic migraine
Beyond the preview
Go deeper on NCT01813591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01813591.